Adagene Inc. (978)

Overview

Adagene Inc. is a clinical stage biotechnology company specialized in the development and production of monoclonal antibody drugs targeting various cancers. Founded in 2011, the company combines innovative research and development strategies to create novel therapies. With its headquarters in Suzhou, China, Adagene is pioneering the innovation of antibody technology to address the unmet needs in cancer treatment. Its approach focuses on developing a diverse pipeline of product candidates that aim to tackle cancers through various mechanisms of action, underscoring its commitment to advancing cancer therapeutics.

Products and Services

ADG106: A human ligand-blocking agonistic anti-CD137 IgG4 monoclonal antibody currently in Phase 1b/2 clinical trials. It's designed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, aiming to enhance the anti-tumor immune response.

ADG126: A masked fully-human anti-CTLA-4 monoclonal antibody in Phase 1 clinical trial. This candidate focuses on the treatment of advanced/metastatic solid tumors, with a novel approach to modulate the immune system.

ADG116: Another anti-CTLA-4 mAb but with a ligand-blocking mechanism, in Phase 1b/2 clinical development. It targets advanced/metastatic solid tumors, proposing a different method of stimulating the immune system to combat cancer.

ADG104: An anti-PD-L1 monoclonal antibody in Phase 2 clinical development. It aims to inhibit the PD-L1 pathway, which is a crucial immune checkpoint in cancer evasion from immune surveillance, for various cancer types.

ADG125: A novel anti-CSF-1R monoclonal antibody in Phase I clinical trial. This product candidate is designed to target the CSF-1R pathway involved in tumor-associated macrophages, which can promote tumor growth and metastasis.

ADG206: A masked, Fc engineered anti-CD137 agonistic POWERbody. This innovative approach seeks to enhance immune response against tumors while potentially reducing side effects associated with CD137 targeting.

ADG153: A masked anti-CD47 IgG1 SAFEbody, currently in preclinical development. It is aimed at treating hematologic and solid tumors by targeting the "don't eat me" signal to promote phagocytosis of cancer cells.

ADG138: A novel HER2xCD3 POWERbody in preclinical for targeting HER2-expressing solid tumors. This product signifies a new approach to recruit and activate T cells specifically against cancer cells expressing HER2.

ADG152: A v POWERbody, in preclinical stage for the potential treatment of off-tumor toxicities. This represents a novel strategy to mitigate side effects of cancer therapies, enhancing patient safety and treatment tolerance.

In addition to these product candidates, Adagene is developing anti-CD28 bispecific POWERbody TCEs, further expanding its portfolio and capabilities in the fight against cancer.